DK2794627T3 - Substituerede nukleosider, nukleotider og analoger deraf - Google Patents
Substituerede nukleosider, nukleotider og analoger deraf Download PDFInfo
- Publication number
- DK2794627T3 DK2794627T3 DK12860391.7T DK12860391T DK2794627T3 DK 2794627 T3 DK2794627 T3 DK 2794627T3 DK 12860391 T DK12860391 T DK 12860391T DK 2794627 T3 DK2794627 T3 DK 2794627T3
- Authority
- DK
- Denmark
- Prior art keywords
- optionally substituted
- alkyl
- compound
- group
- hydrogen
- Prior art date
Links
- 0 CSC[C@@](COP(O)(OP(*I(C=O)(O)O)(O)=O)=O)(C[C@]1F)O[C@]1N(C=CC(N)=N1)C1=O Chemical compound CSC[C@@](COP(O)(OP(*I(C=O)(O)O)(O)=O)=O)(C[C@]1F)O[C@]1N(C=CC(N)=N1)C1=O 0.000 description 7
- BONKAEBSUIVTST-GNYIYVNYSA-N CCO[C@H]([C@@H](C(COC(C=[U])(OCOC(C(C)(C)C)=O)OCOC(C(C)(C)C)=O)O)F)[n]1c(N=C(N)NC2=O)c2nc1 Chemical compound CCO[C@H]([C@@H](C(COC(C=[U])(OCOC(C(C)(C)C)=O)OCOC(C(C)(C)C)=O)O)F)[n]1c(N=C(N)NC2=O)c2nc1 BONKAEBSUIVTST-GNYIYVNYSA-N 0.000 description 1
- SGTLSDOYHKXRQO-UMPJEAMMSA-N CC[C@@](COC(C(C)C)=O)([C@H]([C@H]1F)OCN)O[C@H]1N(C=CC(NC)=N1)C1=O Chemical compound CC[C@@](COC(C(C)C)=O)([C@H]([C@H]1F)OCN)O[C@H]1N(C=CC(NC)=N1)C1=O SGTLSDOYHKXRQO-UMPJEAMMSA-N 0.000 description 1
- OIIMVJKEXGLPGS-UHFFFAOYSA-N CP(O)(OP(C)(OP(C)(OCCCOCCN(C=CC(N)=N1)C1=O)=O)=O)=O Chemical compound CP(O)(OP(C)(OP(C)(OCCCOCCN(C=CC(N)=N1)C1=O)=O)=O)=O OIIMVJKEXGLPGS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Lighting Device Outwards From Vehicle And Optical Signal (AREA)
- Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
- Package Frames And Binding Bands (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (48)
1. Forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf:
hvor: B1A er valgt fra gruppen bestående af:
hvor: RA2 er valgt fra gruppen bestående af hydrogen, halogen og NHRJ2, hvor RJ2 er valgt fra gruppen bestående af hydrogen, C(=O)RK2 og -C(=O)ORL2; RB2 er halogen eller NHRW2, hvor Rw2 er valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret C2-6-alkenyl, en eventuelt substitueret C3-8-cycloalkyl, -C(=O)RM2 og -C(=O)ORN2; Rc2 er hydrogen eller NHR02, hvor R02 er valgt fra gruppen bestående af hydrogen, -C(=O)RP2 og -C(=O)ORQ2; RD2 er valgt fra gruppen bestående af hydrogen, halogen, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret C2-6-alkenyl og en eventuelt substitueret C2-6-alkynyl; RE2 er valgt fra gruppen bestående af hydrogen, hydroxy, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret C3-8-cycloalkyl, -C(=O)RR2 og -C(=O)ORS2; RF2 er valgt fra gruppen bestående af hydrogen, halogen, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret C2-
6-alkenyl og en eventuelt substitueret C2-6-alkynyl ; Y2 og Y3 er uafhængigt N eller CR12, hvor R12 er valgt fra gruppen bestående af hydrogen, halogen, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret C2-6-alkenyl og en eventuelt substitueret C2-6-alkynyl; RG2 er en eventuelt substitueret Ci-6-alkyl; RH2 er hydrogen eller NHRT2, hvor RT2 er valgt fra gruppen bestående af hydrogen, -C(=O)RU2 og -C(=O)ORV2; og RK2, RL2, RM2, RN2, Rp2, RQ2, RR2, Rs2, Ru2 og Rv2 er uafhængigt valgt fra gruppen bestående af Ci-6-alkyl, C2-6-alkenyl, C2-6- alkynyl, C3-6-cycloalkyl, C3-6-cycloalkenyl, C6-io-aryl, heteroaryl, heteroalicyklyl, aryl (Ci-6-alkyl) , heteroaryl (C1-6-alkyl) og heteroalicyklyl (Ci-6-alkyl) ; R1A er valgt fra gruppen bestående af hydrogen, en eventuelt substitueret acyl, en eventuelt substitueret O-bundet aminosyre,
den stiplede linje (------) f formel (I) er fraværende; R2A er valgt fra gruppen bestående af en ikke-substitueret C1-6-alkyl, en halogen-substitueret Ci-6-alkyl, en hydroxy-substitueret Ci-6-alkyl, en alkoxy-substitueret Ci-6-alkyl og en sulfenyl-subs ti tueret Ci-6-alkyl ; R3A er valgt fra gruppen bestående af OH, -OC(=O)R"A og en eventuelt substitueret O-bundet aminosyre; R4A er fluor; R5A er hydrogen; r6a, r7a og r8a er uafhængigt valgt fra gruppen bestående af fraværende, hydrogen, en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24-alkynyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret C3-6-cycloalkenyl, en eventuelt substitueret aryl, en eventuelt substitueret heteroaryl, en eventuelt substitueret aryl(Ci-6-alkyl), en eventuelt substitueret * - (CR15AR16A) p-O-Ci-24-alkyl, en eventuelt substitueret *- (CR17AR18A) q-O-Ci-24-alkenyl,
eller R6A er
og R7A er fraværende eller hydrogen; eller R6A og R7A er taget sammen for at danne en del valgt fra gruppen bestående af en eventuelt substitueret
og en eventuelt substitueret
hvor oxygenatomerne, der er forbundet med R6A og R7A, phosphor og delen danner et seks- til ti-leddet ringsystem;. R9A er valgt fra gruppen bestående af en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24-alkynyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret C3-6-cycloalkenyl, NR30AR31A, en eventuelt substitueret N-bundet aminosyre og et eventuelt substitueret N-bundet aminosyre-esterderivat; R10A og R11A er uafhængigt en eventuelt substitueret N-bundet aminosyre eller et eventuelt substitueret N-bundet aminosyre-esterderivat ; R12A, R13A og R14A er uafhængigt fraværende eller hydrogen;
hver R15A, hver R16A, hver R17A og hver R18A er uafhængigt hydrogen, en eventuelt substitueret Ci-24-alkyl eller alkoxy; R19A, R20A, R22A og R23A er uafhængigt valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-24-alkyl og en eventuelt substitueret aryl; R21A og R24A er uafhængigt valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret aryl, en eventuelt substitueret -O-Ci-24-alkyl og en eventuelt substitueret -O-aryl; R25A og r29a er uafhængigt valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-24-alkyl og en eventuelt substitueret aryl; R26A og R27A er uafhængigt -C^N eller en eventuelt substitueret substituent valgt fra gruppen bestående af C2-8-organylcarbonyl, C2-8-alkoxycarbonyl og C2-8- organylaminocarbonyl; R28A er valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24-alkynyl, en eventuelt substitueret C3-6-cycloalkyl og en eventuelt substitueret C3-6-cycloalkenyl ; R30A og R31A er uafhængigt valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24-alkynyl, en eventuelt substitueret C3-6-cycloalkyl og en eventuelt substitueret C3-6-cycloalkenyl; R"A er en eventuelt substitueret Ci-24-alkyl; m er 0 eller 1; p og q er uafhængigt valgt fra gruppen bestående af 1, 2 og 3; r er 1 eller 2; og Z1A, Z2A, Z3A og Z4A er uafhængigt 0 eller S.
2. Forbindelse ifølge krav 1, hvor R1A er
eller
hvor Z1A, Z2A og Z3A hver er 0.
3. Forbindelse ifølge krav 2, hvor den ene af R6A og R7A er hydrogen, og den anden af R6A og R7A er valgt fra gruppen bestående af en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24-alkynyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret C3-6-cycloalkenyl, en eventuelt substitueret aryl, en eventuelt substitueret heteroaryl og en eventuelt substitueret aryl (Ci-6-alkyl) , den anden af R6A og R7A fortrinsvis er en eventuelt substitueret Ci-24-alkyl; eller R6A og R7A begge er uafhængigt valgt fra gruppen bestående af en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24-alkynyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret C3-6-cycloalkenyl, en eventuelt substitueret aryl, en eventuelt substitueret heteroaryl og en eventuelt substitueret aryl (Ci-6-alkyl) , R6A og R7A fortrinsvis begge er en eventuelt substitueret Ci-24-alkyl; eller den ene af R6A og R7A er valgt fra gruppen bestående af og den anden af
R6A og R7A er valgt fra gruppen bestående af fraværende, hydrogen, en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24-alkynyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret C3-6-cycloalkenyl, en eventuelt substitueret aryl, en eventuelt substitueret heteroaryl og en eventuelt substitueret aryl (Ci-6-alkyl) , R6A og R7A fortrinsvis
begge er uafhænqiqt
valqt fra gruppen bestående af R6A og R7A fortrinsvis begge er
R6A og R7A fortrinsvis begge er
R6A og R7A fortrinsvis begge er
eller R6A og R7A begge er en eventuelt substitueret Ci-24-alkyl; eller R6A og R7A begge er en eventuelt substitueret C2-24- alkenyl; eller R6A og R7A begge er *-(CR15AR16A) p-O-Ci-24-alkyl; eller R6A og R7A begge er *-(CR17AR19A) q-O-C2-24-alkenyl; eller R6A og R7A begge er en eventuelt substitueret aryl; eller R6A og R7A begge er en eventuelt substitueret aryl (Ci-6-alkyl) ; eller R6A og R7A begge er
eller R6A og R7A begge er
eller R6A og R7A er taget sammen for at danne en del valgt fra
gruppen bestående af en eventuelt substitueret
og en eventuelt substitueret
hvor oxygenatomerne, der er forbundet med R6A og R7A, phosphor og delen danner et seks- til ti-leddet ringsystem, R6A og R7A fortrinsvis er taget sammen for at danne en del valgt fra gruppen bestående af
hvor R32A er en eventuelt substitueret aryl, en eventuelt substitueret heteroaryl eller en eventuelt substitueret heterocyclyl.
4. Forbindelse ifølge krav 2, hvor R8A er valgt fra gruppen bestående af fraværende, hydrogen, en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24~alkynyl, en eventuelt substitueret C3-6-cycloalkyl og en eventuelt substitueret C3-6-cycloalkenyl, og R9A er valgt fra gruppen bestående af en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-24~alkynyl, en eventuelt substitueret C3-6-cycloalkyl og en eventuelt substitueret C3-6-cycloalkenyl, R8A fortrinsvis er hydrogen, og R9A er en
eventuelt substitueret Ci-6-alkyl; eller R8A er hydrogen, og R9A er NR30AR31A, hvor R30A og R31A er uafhængigt valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-24-alkyl, en eventuelt substitueret C2-24-alkenyl, en eventuelt substitueret C2-2-alkynyl, en eventuelt substitueret C3-6-cycloalkyl og en eventuelt substitueret C3-6-cycloalkenyl; eller R8A er fraværende eller hydrogen, og R9A er en eventuelt substitueret N-bundet aminosyre eller et eventuelt substitueret N-bundet aminosyre-esterderivat; eller R8A er en eventuelt substitueret aryl, og R9A er en eventuelt substitueret N-bundet aminosyre eller et eventuelt substitueret N-bundet aminosyre-esterderivat .
5. Forbindelse ifølge krav 2, hvor R10A og R11A begge er en eventuelt substitueret N-bundet aminosyre eller et eventuelt substitueret N-bundet aminosyre-esterderivat, R10A og R11A fortrinsvis er uafhængigt valgt fra gruppen bestående af alanin, asparagin, aspartat, cystein, glutamat, glutamin, glycin, prolin, serin, tyrosin, arginin, histidin, isoleucin, leucin, lysin, methionin, phenylalanin, threonin, tryptophan, valin og esterderivater deraf, R10A og R11A fortrinsvis er uafhængigt valgt fra gruppen bestående af alanin-isopropylester, alanin-cyclohexylester, alanin-neopentylester, valin-isopropylester og leucin-isopropylester; eller R10A og R11A uafhængigt har strukturen
hvor r36a er valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret aryl, en eventuelt substitueret aryl(Ci-6-alkyl) og en eventuelt substitueret halogenalkyl, R37A er valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret Ci-6-halogenalkyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret C6-aryl, en eventuelt substitueret C10-aryl og en eventuelt substitueret aryl (Ci-6-alkyl) , og R38A er hydrogen eller en eventuelt substitueret Ci-4-alkyl; eller
R37A og R38A er taget sammen for at danne en eventuelt substitueret C3-6-cycloalkyl, R37A fortrinsvis er en eventuelt substitueret Ci-6-alkyl, R37A fortrinsvis er methyl, R38A fortrinsvis er hydrogen, r36a fortrinsvis er en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret C3-6-cycloalkyl eller en eventuelt substitueret benzyl.
6. Forbindelse ifølge krav 1, hvor R1A er hvor R6A og R7A begge er hydrogen, eller R6A og R7A begge er fraværende; eller R1A er
hvor R6A er
m fortrinsvis er 0, og R7A, R12A og R13A uafhængigt er fraværende eller hydrogen, eller m fortrinsvis er 1, og R7A, R12A, R13A og R14A uafhængigt er fraværende eller hydrogen.
7. Forbindelse ifølge krav 1, hvor R1A er H.
8. Forbindelse ifølge krav 1, hvor R1A er en eventuelt substitueret acyl.
9. Forbindelse ifølge krav 8, hvor den eventuelt substituerede acyl er -C(=O)R39A, hvor R39A er valgt fra gruppen bestående af en eventuelt substitueret Ci-12-alkyl, en eventuelt substitueret C2-i2-alkenyl, en eventuelt substitueret C2-12-alkynyl, en eventuelt substitueret C3-8-cycloalkyl, en eventuelt substitueret Cs-8-cycloalkenyl, en eventuelt substitueret C6-io-aryl, en eventuelt substitueret heteroaryl, en eventuelt substitueret heterocyclyl, en eventuelt
substitueret aryl(Ci-6-alkyl), en eventuelt substitueret heteroaryl(Ci-6-alkyl) og en eventuelt substitueret heterocyclyl (Ci-6-alkyl) , R39A fortrinsvis er substitueret eller ikke-substitueret Ci-12-alkyl.
10. Forbindelse ifølge krav 9, hvor R39A er en ikke-substitueret Ci-12-alkyl.
11. Forbindelse ifølge krav 1, hvor R1A er en eventuelt substitueret O-bundet aminosyre, eller R1A er
hvor r4oa er valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret Ci-6-halogenalkyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret C6-aryl, en eventuelt substitueret C10-aryl og en eventuelt substitueret aryl (Ci-6-alkyl) , og R41A er hydrogen eller en eventuelt substitueret Ci-4-alkyl, eller R40A og R41A er taget sammen for at danne en eventuelt substitueret C3-6-cycloalkyl, R40A fortrinsvis er en eventuelt substitueret Ci-6-alkyl, r4oa fortrinsvis er methyl, R41A fortrinsvis er hydrogen.
12. Forbindelse ifølge krav 1, hvor B1A er
eller
13. Forbindelse ifølge krav 1, hvor B1A er
eller
14. Forbindelse ifølge et hvilket som helst af kravene 1-13, hvor R2A er en halogen-substitueret Ci-6-alkyl eller en sulfenyl-substitueret Ci-6-alkyl.
15. Forbindelse ifølge et hvilket som helst af kravene 1-13, hvor R2A er en halogen-substitueret Ci-6-alkyl.
16. Forbindelse ifølge et hvilket som helst af kravene 1-15, hvor R3A er OH.
17. Forbindelse ifølge et hvilket som helst af kravene 1-15, hvor R3A er -OC(=O)R"A, R3A fortrinsvis er -OC(=O)R"A, hvor R"A er en eventuelt substitueret Ci-8-alkyl.
18. Forbindelse ifølge krav 17, hvor R"A er en ikke-substitueret Ci-s-alkyl.
19. Forbindelse ifølge et hvilket som helst af kravene 1-15, hvor R3A er en eventuelt substitueret O-bundet aminosyre, den O-bundne aminosyre fortrinsvis er valgt fra gruppen bestående af alanin, asparagin, aspartat, cystein, glutamat, glutamin, glycin, prolin, serin, tyrosin, arginin, histidin, isoleucin, leucin, lysin, methionin, phenylalanin, threonin, tryptophan, valin, ornithin, hypusin, 2-aminoisosmørsyre, dehydroalanin, gamma-aminosmørsyre, citrullin, beta-alanin, alfa-ethylglycin, alfa-propylglycin og norleucin; eller R3A er
hvor R42A er valgt fra gruppen bestående af hydrogen, en eventuelt substitueret Ci-6-alkyl, en eventuelt substitueret Ci-6-halogenalkyl, en eventuelt substitueret C3-6-cycloalkyl, en eventuelt substitueret C6~aryl, en eventuelt substitueret Cio-aryl og en eventuelt substitueret aryl (Ci-6-alkyl) , og R43A er hydrogen eller en eventuelt substitueret Ci-4-alkyl, eller R42A og R43A er taget sammen for at danne en eventuelt substitueret C3-6-cycloalkyl, R42A fortrinsvis er en eventuelt substitueret Ci-6-alkyl, R42A fortrinsvis er methyl, R43A fortrinsvis er hydrogen.
20. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er valgt fra gruppen bestående af:
eller et farmaceutisk acceptabelt salt af en hvilket som helst af de foregående forbindelser.
21. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er valgt fra gruppen bestående af:
eller et farmaceutisk acceptabelt salt af en hvilket som helst af de foregående forbindelser.
22. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er valgt fra gruppen bestående af:
eller et farmaceutisk acceptabelt salt af en hvilket som helst af de foregående forbindelser.
23. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er valgt fra gruppen bestående af:
eller et farmaceutisk acceptabelt salt af en hvilket som helst af de foregående forbindelser.
24. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
25. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
26. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
27. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
28. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
29. Forbindelse ifølge et hvilket som helst af kravene 24-28, hvor B1A er cytosin.
30. Forbindelse ifølge et hvilket som helst af kravene 24-28, hvor R1A er hydrogen, et monophosphat, et diphosphat eller et triphosphat.
31. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
32. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
33. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
34. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
35. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
36. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
37. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
38. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
39. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
40. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
41. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
42. Forbindelse ifølge krav 1, hvor forbindelsen med formlen (I) er
eller et farmaceutisk acceptabelt salt deraf.
43. Forbindelse, der har en struktur valgt fra gruppen bestående af:
eller et farmaceutisk acceptabelt salt af en hvilket som helst af de foregående forbindelser.
44. Farmaceutisk sammensætning, der omfatter en effektiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1-43 eller et farmaceutisk acceptabelt salt deraf, og en farmaceutisk acceptabelt bærer, diluent, excipiens eller kombination deraf.
45. Forbindelse ifølge et hvilket som helst af kravene 1-43 til anvendelse til forbedring eller behandling af en viral infektion med paramyxovirus, fortrinsvis en pneumoviral infektion, fortrinsvis en human respiratorisk syncytialvirusinfektion.
46. Forbindelse ifølge et hvilket som helst af kravene 1-43 til anvendelse til hæmning af replikationen af en paramyxovirus, fortrinsvis en pneumoviral infektion, fortrinsvis en human respiratorisk syncytialvirusinfektion.
47. Forbindelse til anvendelse ifølge krav 45 eller 46 i kombination med et eller flere anti-RSV-midler.
48. Forbindelse til anvendelse ifølge krav 47, hvor det ene eller flere RSV-midler er valgt fra gruppen bestående af ribavirin, palivizumab, RSV-IGIV, ALN-RSV01, BMS-433771, RFI-641, RSV604, MDT-637, BTA9881, TMC-353121, MBX-300, YM-53403 og en RSV-F-partikelvaccine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579560P | 2011-12-22 | 2011-12-22 | |
US201261613836P | 2012-03-21 | 2012-03-21 | |
PCT/US2012/071063 WO2013096679A1 (en) | 2011-12-22 | 2012-12-20 | Substituted nucleosides, nucleotides and analogs thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2794627T3 true DK2794627T3 (da) | 2019-01-14 |
Family
ID=48669505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12860391.7T DK2794627T3 (da) | 2011-12-22 | 2012-12-20 | Substituerede nukleosider, nukleotider og analoger deraf |
Country Status (35)
Country | Link |
---|---|
US (4) | US9073960B2 (da) |
EP (2) | EP3466959A1 (da) |
JP (2) | JP6385825B2 (da) |
KR (1) | KR102072041B1 (da) |
CN (2) | CN107459544B (da) |
AP (1) | AP2014007796A0 (da) |
AR (1) | AR089408A1 (da) |
AU (2) | AU2012358803C1 (da) |
BR (1) | BR112014014740B1 (da) |
CA (2) | CA2860289C (da) |
CL (1) | CL2014001641A1 (da) |
CO (1) | CO6990737A2 (da) |
CY (1) | CY1121416T1 (da) |
DK (1) | DK2794627T3 (da) |
EA (1) | EA035493B1 (da) |
EC (1) | ECSP14010277A (da) |
ES (1) | ES2702060T3 (da) |
GE (1) | GEP20166496B (da) |
HK (3) | HK1203076A1 (da) |
HR (1) | HRP20182096T1 (da) |
HU (1) | HUE041509T2 (da) |
IL (2) | IL233152B (da) |
LT (1) | LT2794627T (da) |
MX (2) | MX356509B (da) |
PH (2) | PH12014501436B1 (da) |
PL (1) | PL2794627T3 (da) |
PT (1) | PT2794627T (da) |
RS (1) | RS58099B1 (da) |
SG (3) | SG10201610936RA (da) |
SI (1) | SI2794627T1 (da) |
TW (1) | TWI659963B (da) |
UA (1) | UA117095C2 (da) |
UY (1) | UY34536A (da) |
WO (1) | WO2013096679A1 (da) |
ZA (1) | ZA201404486B (da) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
CA2819041A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
SG10201610936RA (en) | 2011-12-22 | 2017-02-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US8846896B2 (en) | 2012-03-21 | 2014-09-30 | Alios Biopharma, Inc. | Methods of preparing substituted nucleotide analogs |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104203253A (zh) * | 2012-03-21 | 2014-12-10 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸及其类似物 |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
EA027929B1 (ru) | 2012-05-25 | 2017-09-29 | Янссен Сайенсиз Айрлэнд Юси | Нуклеозиды на основе урацила и спирооксетана |
AU2013361193B2 (en) | 2012-12-21 | 2018-05-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9504705B2 (en) | 2013-04-05 | 2016-11-29 | Alios Biopharma, Inc. | Hepatitis C viral infection treatment using a combination of compounds |
DK3013843T3 (da) | 2013-06-26 | 2018-09-03 | Alios Biopharma Inc | Substituerede nukleosider, nukleotider og analoger dertil |
TW201542578A (zh) | 2013-06-26 | 2015-11-16 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
WO2015017675A2 (en) * | 2013-07-31 | 2015-02-05 | Isis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
UA117375C2 (uk) | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
CN104447923B (zh) * | 2013-09-23 | 2018-03-30 | 中国药科大学 | 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途 |
TW201524990A (zh) | 2013-10-11 | 2015-07-01 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
US20160271160A1 (en) | 2013-10-17 | 2016-09-22 | Medivir Ab | Hcv polymerase inhibitors |
UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
EA033866B1 (ru) | 2014-02-06 | 2019-12-03 | Рибосайенс Ллк | 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа |
JP6191989B2 (ja) * | 2014-02-12 | 2017-09-06 | 学校法人東京理科大学 | アデニン誘導体又はその薬理学的に許容しうる塩、その製造方法、及びその用途 |
EP3160475B1 (en) | 2014-06-24 | 2024-01-03 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides and nucleotides to treat filoviridae infections |
DK3160476T3 (da) | 2014-06-24 | 2020-12-21 | Janssen Biopharma Inc | Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner |
BR112017001162A2 (pt) * | 2014-07-22 | 2017-11-14 | Alios Biopharma Inc | métodos para tratar paramixovírus |
TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
SG10201901010PA (en) * | 2014-08-05 | 2019-03-28 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
SG10201810361TA (en) * | 2014-09-26 | 2018-12-28 | Riboscience Llc | 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication |
CA2963686A1 (en) * | 2014-10-08 | 2016-04-14 | Epigenetics Pharma Llc | Silylated pyrimidine prodrugs and methods of their use |
WO2016069489A1 (en) | 2014-10-28 | 2016-05-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
SG11201705069YA (en) * | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EA036776B1 (ru) | 2015-03-11 | 2020-12-21 | Янссен Байофарма, Инк. | Соединения азапиридона и способы их применения |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN107501247A (zh) * | 2016-06-14 | 2017-12-22 | 安徽贝克联合制药有限公司 | 一种尿嘧啶核苷类衍生物的制备方法 |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
TW201811339A (zh) | 2016-08-12 | 2018-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
JP7125144B2 (ja) | 2016-09-09 | 2022-08-24 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
US20180117042A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
WO2019027905A1 (en) | 2017-07-31 | 2019-02-07 | January Therapeutics, Inc. | ORGANOPHOSPHATE DERIVATIVES |
EP3706762A4 (en) | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
WO2021011572A1 (en) * | 2019-07-18 | 2021-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing the antiviral efficacy of rna virus inhibition by combination with modulators of pyrimidine metabolism |
US11708637B2 (en) * | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021195011A1 (en) * | 2020-03-24 | 2021-09-30 | Intrinsic Medicine, Inc. | Immunomodulatory oligosaccharides for the treatment of viral respiratory infection |
CN111892636A (zh) * | 2020-08-07 | 2020-11-06 | 山东大学 | 一种阿兹夫定的合成方法 |
EP4200301A1 (en) | 2020-08-24 | 2023-06-28 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
CN112279877B (zh) * | 2020-12-15 | 2021-08-06 | 南京颐媛生物医学研究院有限公司 | 一种核苷磷酸酯及其合成方法 |
WO2022221514A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
WO2024015916A2 (en) * | 2022-07-13 | 2024-01-18 | Thomas Jefferson University | 4'-alkyne-2'-deoxycytidine-based compounds and anti-cancer uses thereof |
CN116425703A (zh) * | 2023-03-27 | 2023-07-14 | 浙大宁波理工学院 | 一种饱和环醚类化合物c2位环外甲基氘代的方法 |
Family Cites Families (306)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH563405A5 (da) | 1971-09-10 | 1975-06-30 | Duschinsky Robert Dr Schweiz I | |
IL51342A (en) | 1977-01-27 | 1980-11-30 | Abic Ltd | Ethoxyquin derivatives,their preparation and pharmaceutical and veterinary compositions comprising them |
US4230698A (en) | 1978-05-12 | 1980-10-28 | Research Corporation | 2-Substituted arabinofuranosyl nucleosides and nucleotides |
US4211773A (en) | 1978-10-02 | 1980-07-08 | Sloan Kettering Institute For Cancer Research | 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides |
AU5118979A (en) | 1978-10-16 | 1980-04-24 | Takeda Chemical Industries Ltd. | 2,6-diaminoebularines |
US4652554A (en) | 1982-02-22 | 1987-03-24 | St. Jude Children's Research Hospital | Nitro-substituted 1-β-D-arabinofuranosylcytosines |
JPS60228497A (ja) | 1984-04-27 | 1985-11-13 | Sumitomo Chem Co Ltd | 新規なアデニル酸誘導体 |
US4713383A (en) | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
US4626526A (en) | 1984-10-26 | 1986-12-02 | Warner-Lambert Company | (S)-N6 -2-hydroxypropyladenosines |
US4855304A (en) | 1985-01-10 | 1989-08-08 | Repligen Corporation | Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals |
JPS61219478A (ja) | 1985-03-26 | 1986-09-29 | Potsupuribetsuto Fastener Kk | 溶接検知方法及び装置 |
PL144471B1 (en) | 1985-04-22 | 1988-05-31 | Polska Akad Nauk Centrum | Method of obtaining novel 3',5'-cyclic adensine dithiophosphate |
US4762823A (en) | 1985-10-16 | 1988-08-09 | Sloan-Kettering Institute For Cancer Research | Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil |
US4797495A (en) | 1985-11-22 | 1989-01-10 | Burroughs Wellcome Co. | Benzo[c]carbazole propanediol compound and salts thereof |
DK189587A (da) | 1986-04-14 | 1987-10-15 | Shell Int Research | Halogenerede heterocycliske ethere med herbicid virkning |
AU8276187A (en) | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
SU1417408A1 (ru) | 1986-12-02 | 1995-09-10 | Г.П. Акулов | Способ получения меченного тритием дезоксиаденозина |
JPH0699467B2 (ja) | 1987-03-04 | 1994-12-07 | ヤマサ醤油株式会社 | 2▲’▼−デオキシ−2▲’▼(s)−アルキルピリミジンヌクレオシド誘導体 |
AU598946B2 (en) | 1987-06-24 | 1990-07-05 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
DE3730542A1 (de) | 1987-09-11 | 1989-04-06 | Hoechst Ag | Arzneimittel mit einem gehalt an bestimmten 6-mercaptopurin-derivaten, verwendung dieser 6-mercaptopurin-derivate, verfahren zur herstellung der arzneimittel sowie einige neue 6-mercaptopurin-derivate und verfahren zu deren herstellung |
US4880784A (en) | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
HU204843B (en) | 1988-09-27 | 1992-02-28 | Merrell Dow Pharma | Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same |
US5616702A (en) | 1988-11-15 | 1997-04-01 | Merrell Pharmaceuticals Inc. | 2-'-ethenylidene cytidine, uridine and guanosine derivatives |
MX9203459A (es) | 1988-11-15 | 1992-08-01 | Merrell Pharma Inc | Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina. |
ZA898567B (en) | 1988-11-15 | 1990-08-29 | Merrell Dow Pharma | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine,uridine and guanosine derivatives |
AU4479189A (en) | 1988-11-21 | 1990-06-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
SE462497B (sv) | 1988-11-30 | 1990-07-02 | Clas Fredrik Runesson Kaelland | Saett foer att aktivitetsbestaemma polymeraser |
FR2642074B1 (fr) | 1989-01-20 | 1994-04-29 | Oris Ind | Derives de molecules polyhydroxylees permettant l'introduction d'au moins une ramification dans un oligonucleotide |
US5296348A (en) | 1989-05-16 | 1994-03-22 | The Wistar Institute Of Anatomy And Biology | Methods for screening monoclonal antibodies for therapeutic use |
DE3916871A1 (de) | 1989-05-24 | 1990-11-29 | Boehringer Mannheim Gmbh | Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren |
DE3924424A1 (de) | 1989-07-24 | 1991-01-31 | Boehringer Mannheim Gmbh | Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung |
JPH0699711B2 (ja) | 1989-07-25 | 1994-12-07 | 花王株式会社 | 液体洗浄剤組成物 |
US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
EP0942000B1 (en) | 1989-10-24 | 2004-06-23 | Isis Pharmaceuticals, Inc. | 2'-Modified oligonucleotides |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5514786A (en) | 1990-01-11 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Compositions for inhibiting RNA activity |
US5457191A (en) | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
DE69133405T2 (de) | 1990-01-11 | 2005-07-07 | Isis Pharmaceutical, Inc., Carlsbad | Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression |
US5852188A (en) | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
CA2037767A1 (en) | 1990-03-23 | 1991-09-24 | Mark D. Wittman | Conversion of amines to hydroxylamines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5478813A (en) | 1990-05-11 | 1995-12-26 | Banyu Pharmaceutical Co., Ltd. | Antitumor substance BE-13793C derivatives |
AU7623991A (en) | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
GB9012899D0 (en) | 1990-06-09 | 1990-08-01 | Wellcome Found | Anti-hbv pyrimidine nucleoside |
JP2559917B2 (ja) | 1990-06-15 | 1996-12-04 | 三共株式会社 | ピリミジンヌクレオシド誘導体 |
DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
MY106399A (en) | 1990-07-24 | 1995-05-30 | Pfizer | Cephalosporins and homologeus, preparation and pharmaceutical composition |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
IL99125A0 (en) | 1990-08-10 | 1992-07-15 | Gensia Pharma | Derivatives of imidazole analog of aica riboside and their use |
US5777100A (en) | 1990-08-10 | 1998-07-07 | Gensia Inc. | AICA riboside analogs |
US6262241B1 (en) | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
US5420115A (en) * | 1990-09-10 | 1995-05-30 | Burroughs Wellcome Co. | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
WO1992012718A1 (en) | 1991-01-23 | 1992-08-06 | Gensia, Inc. | Adenosine kinase inhibitors |
US5171849A (en) | 1991-04-19 | 1992-12-15 | The Ohio State University Research Foundation | 2' and 3' Carboranyl uridines and their diethyl ether adducts |
US5446031A (en) | 1991-04-24 | 1995-08-29 | Yamasa Shuyu Kabushiki Kaisha | 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives |
GB9111580D0 (en) | 1991-05-30 | 1991-07-24 | Wellcome Found | Nucleoside derivative |
US5192764A (en) | 1991-05-30 | 1993-03-09 | Research Foundation Of State Of N.Y. | Pyrazinone n-oxide nucleosides and analogs thereof |
US5508407A (en) | 1991-07-10 | 1996-04-16 | Eli Lilly And Company | Retroviral protease inhibitors |
JPH0551395A (ja) | 1991-08-21 | 1993-03-02 | Teijin Ltd | ペンタフルオロプロピオニル化(デオキシ)ウリジンおよびそれを用いる(デオキシ)ウリジンの測定方法 |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
DE4131579A1 (de) | 1991-09-23 | 1993-03-25 | Boehringer Mannheim Gmbh | Thiadiazolo(4,3-a)pyridinderivate, verfahren zu ihrer herstellung und diese enthaltenden arzneimittel |
FI105556B (fi) | 1991-09-30 | 2000-09-15 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
DE637965T1 (de) | 1991-11-26 | 1995-12-14 | Gilead Sciences Inc | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen. |
IT1249732B (it) | 1991-11-26 | 1995-03-09 | Angeletti P Ist Richerche Bio | Oligonucleotidi antisenso. |
FR2684997A1 (fr) | 1991-12-12 | 1993-06-18 | Centre Nat Rech Scient | Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique. |
FR2688003B1 (fr) | 1992-02-28 | 1995-06-30 | Univ Limoges | Derives de nucleosides, leur preparation et leurs applications biologiques. |
US5543507A (en) | 1992-03-05 | 1996-08-06 | Isis Pharmaceuticals, Inc. | Covalently cross-linked oligonucleotides |
CA2117891C (en) | 1992-04-10 | 1998-07-07 | Sai P. Sunkara | Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5808139A (en) | 1992-04-21 | 1998-09-15 | Ligand Pharmaceuticals Incorporated | Non-steroid progesterone receptor agonist and antagonist and compounds and methods |
HU217963B (hu) | 1992-05-12 | 2000-05-28 | Merrell Dow Pharmaceuticals Inc. | Eljárás ribonukleotid-reduktáz inhibitorok előállítására |
DE4217679C2 (de) | 1992-05-26 | 1998-02-19 | Genieser Hans Gottfried Dr | Cyclische Guanosin-3',5'-phosphorothioat-Derivate |
US5625056A (en) | 1992-05-26 | 1997-04-29 | Biolog Life Science Institute | Derivatives of cyclic guanosine-3',5'-monophosphorothioate |
CA2140428C (en) | 1992-07-23 | 2003-07-08 | Daniel Peter Claude Mcgee | Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof |
HU9501994D0 (en) | 1993-03-31 | 1995-09-28 | Sterling Winthrop Inc | Novel 5'-substituted nucleosides and oligomers produced therefrom |
BR9407510A (pt) | 1993-09-17 | 1997-01-07 | Gilead Sciences Inc | Análogos de nucleotideo |
DE4341161A1 (de) | 1993-12-02 | 1995-06-08 | Michael Prof Dr Zeppezauer | Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
JPH07242544A (ja) | 1994-03-01 | 1995-09-19 | Takeda Chem Ind Ltd | 抗腫瘍剤 |
US5681940A (en) | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
US6004939A (en) | 1995-07-06 | 1999-12-21 | Ctrc Research Foundation Board Of Regents | Methods for modulation and inhibition of telomerase |
HU220105B (hu) | 1996-01-23 | 2001-10-28 | Icn Pharmaceuticals, Inc. | Ribavirin alkalmazása TH1- és TH2- válaszreakció befolyásolására szolgáló készítmények előállítására |
JPH09328497A (ja) * | 1996-04-12 | 1997-12-22 | Yamasa Shoyu Co Ltd | 4’−フルオロメチルヌクレオシド |
PL187107B1 (pl) | 1996-10-16 | 2004-05-31 | Icn Pharmaceuticals | L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie |
CZ126799A3 (cs) | 1996-10-16 | 1999-07-14 | Icn Pharmaceuticals | Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují |
US20030064945A1 (en) | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
CN1273476C (zh) | 1997-09-12 | 2006-09-06 | 埃克西康有限公司 | 寡核苷酸类似物 |
US20030203862A1 (en) | 1998-03-26 | 2003-10-30 | Miraglia Loren J. | Antisense modulation of MDM2 expression |
US6127121A (en) | 1998-04-03 | 2000-10-03 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination |
WO1999061583A2 (en) | 1998-05-28 | 1999-12-02 | Incara Pharmaceuticals Corp. | Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction |
DE19855963A1 (de) | 1998-12-04 | 2000-06-08 | Herbert Schott | Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung |
JP2002540118A (ja) * | 1999-03-18 | 2002-11-26 | エクシコン エ/エス | キシロ−lna類似体 |
NZ514348A (en) * | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
EP1177201B1 (en) | 1999-05-12 | 2003-09-24 | Yamasa Corporation | 4'-c-ethynyl pyrimidine nucleosides |
JP4076114B2 (ja) | 1999-05-12 | 2008-04-16 | ヤマサ醤油株式会社 | 4’−c−エチニルプリンヌクレオシド化合物 |
US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
IL147908A0 (en) | 1999-08-27 | 2002-08-14 | Icn Pharmaceuticals | PYRROLO[2,3-d] PYRIMIDINE NUCLEOSIDE ANALOGS |
IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
JP2003516962A (ja) | 1999-12-16 | 2003-05-20 | アルコン,インコーポレイテッド | 視神経損傷および網膜損傷の処置のためのアデノシンキナーゼのインヒビター |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
JP2002322192A (ja) * | 2000-08-10 | 2002-11-08 | Sankyo Co Ltd | 2’−o,4’−c−架橋ヌクレオシドトリリン酸体 |
JP2004313002A (ja) | 2000-10-12 | 2004-11-11 | Mitsui Chemicals Inc | ヌクレオシドの製造方法 |
WO2002031176A1 (fr) | 2000-10-12 | 2002-04-18 | Mitsui Chemicals, Inc. | Procédé permettant la production de nucléosides |
BR0114837A (pt) * | 2000-10-18 | 2006-05-09 | Pharmasset Ltd | nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal |
ATE292973T1 (de) | 2001-01-16 | 2005-04-15 | Can Fite Biopharma Ltd | Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation |
WO2002057287A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
JP2002302498A (ja) | 2001-04-03 | 2002-10-18 | Mitsui Chemicals Inc | ヌクレオシドの工業的な製造法 |
US20040204481A1 (en) | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
WO2003070912A2 (en) | 2001-06-06 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP1390472A4 (en) | 2001-05-29 | 2004-11-17 | Sirna Therapeutics Inc | NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
JP2003012690A (ja) | 2001-07-03 | 2003-01-15 | Mitsui Chemicals Inc | 置換イミダゾール誘導体又は置換ベンズイミダゾール誘導体を用いたヌクレオチドの製造法 |
JP2003055392A (ja) | 2001-08-08 | 2003-02-26 | Mitsui Chemicals Inc | 1−リン酸化糖の製造法並びにヌクレオシドの製造法 |
WO2003015798A1 (en) * | 2001-08-14 | 2003-02-27 | Toyama Chemical Co., Ltd. | Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue |
US6962991B2 (en) | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
JP2005504087A (ja) | 2001-09-28 | 2005-02-10 | イデニクス(ケイマン)リミテツド | 4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物 |
WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
US7037718B2 (en) | 2001-10-26 | 2006-05-02 | Cornell Research Foundation, Inc. | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
US7125982B1 (en) | 2001-12-05 | 2006-10-24 | Frayne Consultants | Microbial production of nuclease resistant DNA, RNA, and oligo mixtures |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
EP1572705A2 (en) * | 2002-01-17 | 2005-09-14 | Ribapharm, Inc. | Sugar modified nucleosides as viral replication inhibitors |
CA2477741A1 (en) * | 2002-02-28 | 2003-09-04 | Biota, Inc. | Nucleotide mimics and their prodrugs |
WO2003073989A2 (en) | 2002-02-28 | 2003-09-12 | Biota, Inc. | Nucleoside 5'-monophosphate mimics and their prodrugs |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
JP2003310293A (ja) | 2002-04-26 | 2003-11-05 | Mitsui Chemicals Inc | ヌクレオシド化合物の製造法 |
US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
ES2290448T3 (es) | 2002-05-08 | 2008-02-16 | Santaris Pharma A/S | Sistesis de derivados de acidos nucleicos bloqueados. |
US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
JP4902958B2 (ja) | 2002-06-07 | 2012-03-21 | ユニバーシテール・メディッシュ・セントラム・ユトレヒト | cAMPによって直接活性化される交換タンパク質(Epac)の活性をモジュレートするための新規な化合物 |
BR0312278A (pt) | 2002-06-28 | 2007-06-19 | Idenix Cayman Ltd | éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae |
PL374792A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
JP2005533817A (ja) | 2002-06-28 | 2005-11-10 | イデニクス(ケイマン)リミテツド | フラビウィルス科ウィルス感染治療用の修飾2′および3′−ヌクレオシドプロドラッグ |
AU2003259735A1 (en) | 2002-08-08 | 2004-02-25 | Sirna Therapeutics, Inc. | Small-mer compositions and methods of use |
US7094768B2 (en) | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
AU2003274652A1 (en) | 2002-10-23 | 2004-05-13 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
US20040229840A1 (en) | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7393954B2 (en) | 2002-12-12 | 2008-07-01 | Reliable Biopharmaceutical Corporation | Process for the production of pentostatin aglycone and pentostatin |
AU2003300901A1 (en) | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
US7002006B2 (en) | 2003-02-12 | 2006-02-21 | Isis Pharmaceuticals, Inc. | Protection of nucleosides |
KR20110079783A (ko) * | 2003-02-19 | 2011-07-07 | 예일 유니버시티 | 항-바이러스 뉴클레오시드 유사체 및 바이러스 감염, 특히 에이치아이브이 감염의 치료방법 |
AU2003225705A1 (en) | 2003-03-07 | 2004-09-30 | Ribapharm Inc. | Cytidine analogs and methods of use |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
WO2005020884A2 (en) | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
JP2007504152A (ja) | 2003-08-27 | 2007-03-01 | ビオタ, インコーポレイテッド | 治療剤としての新規三環ヌクレオシドまたはヌクレオチド |
US7425544B2 (en) | 2003-09-18 | 2008-09-16 | Eli Lilly And Company | Modulation of eIF4E expression |
WO2005034878A2 (en) | 2003-10-08 | 2005-04-21 | President And Fellows Of Harvard College | Pyrovalerone analogs and therapeutic uses thereof |
DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
US7144868B2 (en) | 2003-10-27 | 2006-12-05 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US8637650B2 (en) | 2003-11-05 | 2014-01-28 | Genovoxx Gmbh | Macromolecular nucleotide compounds and methods for using the same |
JP2007517019A (ja) | 2003-12-29 | 2007-06-28 | カン−フィテ・バイオファーマ・リミテッド | 多発性硬化症の治療方法 |
DE102004009704A1 (de) | 2004-02-27 | 2005-09-15 | Dmitry Cherkasov | Makromolekulare Nukleotidverbindungen und Methoden zu deren Anwendung |
GB0413726D0 (en) | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
US20060040944A1 (en) | 2004-06-23 | 2006-02-23 | Gilles Gosselin | 5-Aza-7-deazapurine derivatives for treating Flaviviridae |
US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
WO2006011130A1 (en) | 2004-07-28 | 2006-02-02 | Can-Fite Biopharma Ltd. | Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren’s syndrome |
US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
EP1807440B1 (en) | 2004-11-03 | 2020-02-19 | The University of Kansas | Novobiocin analogues as anticancer agents |
WO2006097320A2 (de) | 2005-03-17 | 2006-09-21 | Genovoxx Gmbh | Makromolekulare nukleotidverbindungen und methoden zu deren anwendung |
BRPI0517639A (pt) | 2004-11-08 | 2008-10-14 | Can Fite Biopharma Ltd | método para o tratamento de ressorção óssea acelerada, composição farmacêutica, e, uso de um agonista de a3ar |
JP2006131596A (ja) | 2004-11-09 | 2006-05-25 | Univ Nagoya | ヌクレオチド及びその誘導体の製造方法 |
US8399428B2 (en) * | 2004-12-09 | 2013-03-19 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
EP1828217A2 (en) | 2004-12-16 | 2007-09-05 | Febit Biotech GmbH | Polymerase-independent analysis of the sequence of polynucleotides |
WO2006084281A1 (en) | 2005-02-04 | 2006-08-10 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
EP1858889A1 (en) | 2005-03-08 | 2007-11-28 | Biota Scientific Management Pty. Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
JP2008535932A (ja) | 2005-03-09 | 2008-09-04 | イデニクス(ケイマン)リミテツド | 抗ウィルス剤としての非天然塩基を有するヌクレオシド |
JP2006248949A (ja) | 2005-03-09 | 2006-09-21 | Univ Nagoya | ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法 |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US20060229265A1 (en) | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
EP1876894A1 (en) | 2005-04-26 | 2008-01-16 | The Board of Trustees of the University of Illinois | Nucleoside compounds and methods of use thereof |
WO2007006544A2 (en) | 2005-07-12 | 2007-01-18 | Vrije Universiteit Brussel | Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders |
WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
CA2618335C (en) | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
CN101321775B (zh) | 2005-10-03 | 2012-05-23 | 大学健康网络 | 用于治疗疟疾的odcase抑制剂 |
US7884202B2 (en) | 2005-11-09 | 2011-02-08 | Tosoh Corporation | Nucleobase having perfluoroalkyl group and process for producing the same |
WO2007113538A1 (en) | 2006-04-03 | 2007-10-11 | Astrazeneca Ab | Substituted adenines and the uses thereof |
WO2007149554A2 (en) | 2006-06-22 | 2007-12-27 | The Johns Hopkins University | Methods for restoring neural function |
GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
RS51549B (en) | 2006-08-08 | 2011-06-30 | Millennium Pharmaceuticals Inc. | HETEROARIL UNITS USEFUL AS INVESTIGATIVE ENZYME E1 INHIBITORS |
DE102006037786A1 (de) | 2006-08-11 | 2008-03-20 | Resprotect Gmbh | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
GB0618235D0 (en) | 2006-09-15 | 2006-10-25 | Lauras As | Process |
WO2008083465A1 (en) | 2007-01-08 | 2008-07-17 | University Health Network | Pyrimidine derivatives as anticancer agents |
WO2008086042A2 (en) | 2007-01-10 | 2008-07-17 | Chisari Francis V | Preventing infection by a measles or respiratory syncytial virus |
MX2009007333A (es) | 2007-01-12 | 2009-08-31 | Biocryst Pharm Inc | Analogos de nucleosidos antivirales. |
WO2008089439A2 (en) | 2007-01-18 | 2008-07-24 | Fred Hutchinson Cancer Research Center | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
EP2993473A1 (en) | 2007-01-30 | 2016-03-09 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
JP2010518015A (ja) | 2007-01-31 | 2010-05-27 | アリオス バイオファーマ インク. | 2−5aアナログ類およびそれらの使用方法 |
WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
JP2008214305A (ja) | 2007-03-07 | 2008-09-18 | Kotobuki Seiyaku Kk | 置換アミン誘導体及びこれを有効成分とする医薬組成物 |
WO2008117046A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolo [4, 3-d] pyrimidines as antibacterial compounds |
WO2008117047A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds |
US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US20080255038A1 (en) | 2007-04-11 | 2008-10-16 | Samuel Earl Hopkins | Pharmaceutical compositions |
EP1980568A1 (de) | 2007-04-13 | 2008-10-15 | Eberhard Karls Universität Tübingen | Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung |
PL2014771T3 (pl) | 2007-06-25 | 2015-05-29 | Anadys Pharmaceuticals Inc | Ciągły proces hydrolizy enzymatycznej |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
EP2019100A1 (en) | 2007-07-19 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
US20090076062A1 (en) | 2007-09-13 | 2009-03-19 | Juergen Klaus Maibaum | Organic Compounds |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
CN101820883B (zh) | 2007-10-15 | 2013-03-20 | 坎-菲特生物药物有限公司 | A3ar激动剂在用于制备刺激肝细胞增殖的药物中的应用 |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
US20090176732A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma Inc. | Protected nucleotide analogs |
WO2009086201A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents |
BRPI0908849A2 (pt) | 2008-02-22 | 2015-08-25 | Irm Llc | Composto e composições como c-kit e inibidores de pdgfr quinase |
WO2009125841A1 (ja) | 2008-04-10 | 2009-10-15 | 浜理薬品工業株式会社 | 5-メチルウリジンを出発原料とするエチニルチミジン化合物の製造方法 |
WO2009126293A2 (en) | 2008-04-11 | 2009-10-15 | Yale University | Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase |
EP3042660A3 (en) | 2008-04-15 | 2016-10-26 | RFS Pharma, LLC. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
US20090274686A1 (en) | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
DE102008035299A1 (de) | 2008-07-29 | 2010-02-04 | Resprotect Gmbh | Konjugat aus Hsp27 und einem Nukleosid, Verfahren zur Phosphorylierung von Hsp27 und Verwendung zur Herstellung eines Arzneimittels |
GB0815315D0 (en) | 2008-08-21 | 2008-09-24 | Univ Leiden | Organ protection |
GB0815968D0 (en) * | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
CN102216316A (zh) | 2008-09-05 | 2011-10-12 | 寿制药株式会社 | 取代胺衍生物及以其为有效成分的药物组合物 |
WO2010030858A1 (en) | 2008-09-15 | 2010-03-18 | Enanta Pharmaceuticals, Inc. | 4'-allene-substituted nucleoside derivatives |
WO2010039548A2 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
AU2009308217B2 (en) | 2008-10-24 | 2016-01-21 | Ionis Pharmaceuticals, Inc. | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
JP5793084B2 (ja) | 2008-12-23 | 2015-10-14 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドの合成 |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
BRPI1005401A2 (pt) | 2009-02-06 | 2019-04-02 | Rfs Pharma, Llc | pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais |
EP2669290A1 (en) * | 2009-03-02 | 2013-12-04 | Alnylam Pharmaceuticals Inc. | Nucleic Acid Chemical Modifications |
WO2010108135A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
AU2010226466A1 (en) | 2009-03-20 | 2011-10-20 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
MX2011012068A (es) * | 2009-05-12 | 2012-06-08 | Southern Res Inst | Nucleosidos 2'-fluoro arabino y su utilizaicon. |
EP2264169A1 (en) | 2009-06-15 | 2010-12-22 | Qiagen GmbH | Modified siNA |
WO2011005595A2 (en) | 2009-06-24 | 2011-01-13 | Alios Biopharma, Inc. | 2-5a analogs and their methods of use |
WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
US20150018301A1 (en) | 2009-11-06 | 2015-01-15 | The Johns Hopkins University | LRRK-2-Mediated Neuronal Toxicity |
WO2011100131A2 (en) | 2010-01-28 | 2011-08-18 | Alnylam Pharmacuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
US20130109645A1 (en) | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
KR101701510B1 (ko) | 2010-07-09 | 2017-02-01 | 엘지이노텍 주식회사 | 발광소자 |
BR112013001267A2 (pt) | 2010-07-19 | 2016-05-17 | Gilead Sciences Inc | métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro |
CR20170278A (es) | 2010-07-22 | 2017-09-29 | Gilead Sciences Inc | Métodos y compuestos para tratar infecciones virales por paramyxoviridae |
JP5640552B2 (ja) | 2010-08-23 | 2014-12-17 | セイコーエプソン株式会社 | 制御装置、表示装置及び表示装置の制御方法 |
CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
AR083221A1 (es) | 2010-09-29 | 2013-02-06 | Univ Nac Quilmes | Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato |
BR112013013659B8 (pt) | 2010-12-03 | 2024-02-27 | Epizyme Inc | Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia |
CA2819041A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
WO2012094248A1 (en) | 2011-01-03 | 2012-07-12 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
WO2013019874A1 (en) | 2011-08-01 | 2013-02-07 | Mbc Pharma, Inc. | Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates |
CN103102345B (zh) | 2011-11-14 | 2015-06-03 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
SG10201610936RA (en) | 2011-12-22 | 2017-02-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
LT2794600T (lt) | 2011-12-22 | 2018-02-26 | Novartis Ag | 2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito |
MY192815A (en) | 2011-12-22 | 2022-09-09 | Connexios Life Sciences Pvt Ltd | Derivatives of aza adamantanes and uses thereof |
AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
RU2669695C2 (ru) | 2011-12-22 | 2018-10-15 | Конекшис Лайф Сайенсиз Пвт. Лтд. | Циклические амидные производные как ингибиторы 11-бета-гидроксистероид-дегидрогеназы и их применение |
EP3351552B1 (en) | 2012-03-13 | 2021-05-19 | Gilead Sciences, Inc. | 2'-substituted carba-nucleoside analogs for antiviral treatment |
WO2013138210A1 (en) | 2012-03-14 | 2013-09-19 | Ning Xi | Substituted cyclic compounds and methods of use |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US8846896B2 (en) | 2012-03-21 | 2014-09-30 | Alios Biopharma, Inc. | Methods of preparing substituted nucleotide analogs |
WO2013142159A1 (en) | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
CN104203253A (zh) | 2012-03-21 | 2014-12-10 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸及其类似物 |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
AU2013266393B2 (en) | 2012-05-22 | 2017-09-28 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
CN104583224A (zh) | 2012-07-03 | 2015-04-29 | 百时美施贵宝公司 | 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法 |
WO2014022639A1 (en) | 2012-08-01 | 2014-02-06 | Vertex Pharmaceuticals Incorporated | Solid forms of (4-isopropoxy-3-methoxyphenyl)(2'-methyl-6'-(trifluoromethyl)-3',4'-dihydro-2'h-spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]-1-yl)methanone |
EP2882750A4 (en) | 2012-08-10 | 2016-08-17 | Epizyme Inc | INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF |
WO2014038561A1 (ja) | 2012-09-04 | 2014-03-13 | 株式会社ダナフォーム | 化合物、核酸、標識物質および検出方法 |
KR102281288B1 (ko) | 2012-09-26 | 2021-07-26 | 에프. 호프만-라 로슈 아게 | 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법 |
SG11201502120XA (en) | 2012-09-26 | 2015-04-29 | Merck Patent Gmbh | Quinazolinone derivatives as parp inhibitors |
CN104884462A (zh) | 2012-10-29 | 2015-09-02 | 共晶制药股份有限公司 | 用于治疗病毒感染和癌症的嘧啶核苷及其单磷酸酯前药 |
GB201220843D0 (en) | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
AU2013361193B2 (en) | 2012-12-21 | 2018-05-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US20140309413A1 (en) | 2013-03-11 | 2014-10-16 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
US9504705B2 (en) | 2013-04-05 | 2016-11-29 | Alios Biopharma, Inc. | Hepatitis C viral infection treatment using a combination of compounds |
TW201542578A (zh) | 2013-06-26 | 2015-11-16 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
DK3013843T3 (da) | 2013-06-26 | 2018-09-03 | Alios Biopharma Inc | Substituerede nukleosider, nukleotider og analoger dertil |
TW201524990A (zh) | 2013-10-11 | 2015-07-01 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
DK3160476T3 (da) | 2014-06-24 | 2020-12-21 | Janssen Biopharma Inc | Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner |
EP3160475B1 (en) | 2014-06-24 | 2024-01-03 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides and nucleotides to treat filoviridae infections |
SG11201610259SA (en) | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Methods of preparing substituted nucleotide analogs |
BR112017001162A2 (pt) | 2014-07-22 | 2017-11-14 | Alios Biopharma Inc | métodos para tratar paramixovírus |
SG10201901010PA (en) | 2014-08-05 | 2019-03-28 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
US9981175B2 (en) | 2014-09-12 | 2018-05-29 | Dan DeLaRosa | Taekwondo bag |
WO2016069489A1 (en) | 2014-10-28 | 2016-05-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
TW201811339A (zh) | 2016-08-12 | 2018-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
US20180117042A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
-
2012
- 2012-12-20 SG SG10201610936RA patent/SG10201610936RA/en unknown
- 2012-12-20 AP AP2014007796A patent/AP2014007796A0/xx unknown
- 2012-12-20 WO PCT/US2012/071063 patent/WO2013096679A1/en active Application Filing
- 2012-12-20 RS RS20181560A patent/RS58099B1/sr unknown
- 2012-12-20 UY UY0001034536A patent/UY34536A/es not_active Application Discontinuation
- 2012-12-20 BR BR112014014740-0A patent/BR112014014740B1/pt not_active IP Right Cessation
- 2012-12-20 US US13/721,988 patent/US9073960B2/en not_active Expired - Fee Related
- 2012-12-20 MX MX2014007480A patent/MX356509B/es active IP Right Grant
- 2012-12-20 CA CA2860289A patent/CA2860289C/en active Active
- 2012-12-20 EP EP18196511.2A patent/EP3466959A1/en not_active Ceased
- 2012-12-20 CN CN201710692170.4A patent/CN107459544B/zh not_active Expired - Fee Related
- 2012-12-20 KR KR1020147019834A patent/KR102072041B1/ko active IP Right Grant
- 2012-12-20 CN CN201280069475.5A patent/CN104114568B/zh not_active Expired - Fee Related
- 2012-12-20 ES ES12860391T patent/ES2702060T3/es active Active
- 2012-12-20 GE GEAP201213529A patent/GEP20166496B/en unknown
- 2012-12-20 JP JP2014548912A patent/JP6385825B2/ja not_active Expired - Fee Related
- 2012-12-20 HU HUE12860391A patent/HUE041509T2/hu unknown
- 2012-12-20 PT PT12860391T patent/PT2794627T/pt unknown
- 2012-12-20 SG SG10201913554YA patent/SG10201913554YA/en unknown
- 2012-12-20 PL PL12860391T patent/PL2794627T3/pl unknown
- 2012-12-20 CA CA3107640A patent/CA3107640A1/en not_active Abandoned
- 2012-12-20 SG SG11201402826YA patent/SG11201402826YA/en unknown
- 2012-12-20 DK DK12860391.7T patent/DK2794627T3/da active
- 2012-12-20 UA UAA201408335A patent/UA117095C2/uk unknown
- 2012-12-20 AU AU2012358803A patent/AU2012358803C1/en not_active Ceased
- 2012-12-20 EP EP12860391.7A patent/EP2794627B1/en active Active
- 2012-12-20 EA EA201491040A patent/EA035493B1/ru not_active IP Right Cessation
- 2012-12-20 SI SI201231479T patent/SI2794627T1/sl unknown
- 2012-12-20 LT LTEP12860391.7T patent/LT2794627T/lt unknown
- 2012-12-21 AR ARP120104913A patent/AR089408A1/es active IP Right Grant
- 2012-12-21 TW TW101149140A patent/TWI659963B/zh not_active IP Right Cessation
-
2014
- 2014-06-16 IL IL233152A patent/IL233152B/en active IP Right Grant
- 2014-06-18 ZA ZA2014/04486A patent/ZA201404486B/en unknown
- 2014-06-19 CL CL2014001641A patent/CL2014001641A1/es unknown
- 2014-06-19 MX MX2018006658A patent/MX2018006658A/es unknown
- 2014-06-20 PH PH12014501436A patent/PH12014501436B1/en unknown
- 2014-06-25 CO CO14137284A patent/CO6990737A2/es unknown
- 2014-07-22 EC ECIEPI201410277A patent/ECSP14010277A/es unknown
-
2015
- 2015-04-13 HK HK15103587.6A patent/HK1203076A1/xx not_active IP Right Cessation
- 2015-04-14 HK HK15103629.6A patent/HK1203204A1/xx unknown
- 2015-07-02 US US14/790,645 patent/US10464965B2/en not_active Expired - Fee Related
- 2015-09-30 PH PH12015502273A patent/PH12015502273A1/en unknown
-
2018
- 2018-05-15 AU AU2018203423A patent/AU2018203423B2/en not_active Ceased
- 2018-06-08 HK HK18107469.7A patent/HK1248239A1/zh unknown
- 2018-08-08 JP JP2018149017A patent/JP6718487B2/ja not_active Expired - Fee Related
- 2018-12-11 HR HRP20182096TT patent/HRP20182096T1/hr unknown
- 2018-12-13 CY CY20181101341T patent/CY1121416T1/el unknown
-
2019
- 2019-07-31 US US16/528,414 patent/US11021509B2/en active Active
-
2020
- 2020-02-27 IL IL272953A patent/IL272953B/en unknown
-
2021
- 2021-02-17 US US17/178,151 patent/US20210179656A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11021509B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
DK2827875T3 (da) | Substituerede nukleosider, nukleotider og analoger dertil | |
US10485815B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
USRE48171E1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
NZ627179B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
OA17044A (en) | Substituted nucleosides, nucleotides and analogs thereof. | |
OA17135A (en) | Substituted nucleosides, nucleotides and analogs thereof |